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Abstract
Zoonotic A(H7N9) avian influenza viruses emerged in China in 2013 and continue to be a threat 
to human public health, having infected over 800 individuals with a mortality rate approaching 
40%. Treatment options for people infected with A(H7N9) include the use of neuraminidase (NA) 
inhibitors. However, like other influenza viruses, A(H7N9) can become resistant to these drugs. 
The use of monoclonal antibodies is a rapidly developing strategy for controlling influenza virus 
infection. Here we generated a murine monoclonal antibody (3c10-3) directed against the NA of 
A(H7N9) and show that prophylactic systemic administration of 3c10-3 fully protected mice from 
lethal challenge with wild-type A/Anhui/1/2013 (H7N9). Further, post-infection treatment with a 
single systemic dose of 3c10-3 at either 24, 48 or 72 h post A(H7N9) challenge resulted in both 
dose- and time-dependent protection of up to 100% of mice, demonstrating therapeutic potential 
for 3c10-3. Epitope mapping revealed that 3c10-3 binds near the enzyme active site of NA, and 
functional characterization showed that 3c10-3 inhibits the enzyme activity of NA and restricts the 
cell-to-cell spread of the virus in cultured cells. Affinity analysis also revealed that 3c10-3 binds 
equally well to recombinant NA of wild-type A/Anhui/1/2013 and to a variant NA carrying a 
R289K mutation known to infer NAI resistance. These results suggest that 3c10-3 has the potential 
to be used as a therapeutic to treat A(H7N9) infections either as an alternative to, or in 
combination with, current NA antiviral inhibitors.
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1. Introduction
Influenza viruses pose a significant threat to global public health, affecting human as well as 
agricultural and wild animal species. Occasionally viruses cross the species barrier and pose 
*Corresponding author. Influenza Division, MS G-16, 1600 Clifton Rd NE, Atlanta, GA 30333, USA., ite1@cdc.gov (I.A. York). 
HHS Public Access
Author manuscript
Antiviral Res. Author manuscript; available in PMC 2017 December 14.
Published in final edited form as:
Antiviral Res. 2016 November ; 135: 48–55. doi:10.1016/j.antiviral.2016.10.001.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the potential for a global pandemic. Avian influenza A viruses of the H7N9 subtype first 
infected humans in China in 2013 and have since resulted in 786 confirmed cases and 307 
deaths (case-fatality risk 39%) as of May 2016 (Food and Agriculture Organization of the 
United Nations, 2016). Most infections are believed to result from direct exposure to poultry, 
but there is evidence that limited person-to-person spread has occurred (Farooqui et al., 
2016; Qi et al., 2013). Although A(H7N9) is not yet capable of establishing sustained 
person-to-person transmission, these viruses are considered to have pandemic potential due 
to their ability to bind both avian and human-like receptors (α2,3 and α2,6-linked sialic 
acid, respectively) (Shi et al., 2013; Yang et al., 2013; Zhou et al., 2013).
Currently, there is no commercially-available vaccine for the prevention of A(H7N9) 
infection and the main treatment strategy for avian influenza infection consists of supportive 
medical care and the use of neuraminidase inhibitors (NAIs). The World Health 
Organization recommends treatment with NAIs as quickly as possible, for patients with 
suspected or confirmed A(H7N9) virus infection but their clinical effectiveness against this 
virus remains unknown. For seasonal viruses, the US Centers for Disease Control and 
Prevention (CDC) recommends the use of NAIs for patients with suspected or confirmed 
influenza who are hospitalized or at high risk for complications due to influenza, including 
patients less than 2 and more than 65 years of age, those with underlying medical conditions 
or compromised immunity, and pregnant women. However, NAIs only consistently reduce 
the severity of disease if taken within 48 h of the onset of clinical symptoms (Dobson et al., 
2015). Further, there is evidence that A(H7N9) can gain NAI resistance while maintaining in 
vivo virulence in animal models (Hai et al., 2013; Itoh et al., 2015). Supporting this, virus 
with reduced susceptibility to the commonly-used NAI oseltamivir has been isolated from 
A(H7N9) patients treated with NAI (Hu et al., 2013). Thus, it is important to establish 
alternative antiviral options to mitigate the severity of disease caused by A(H7N9) infection.
The two major influenza envelope glycoproteins, hemagglutinin (HA) and NA, are the 
primary viral components known to induce protective humoral immune responses upon 
influenza vaccination or viral infection (Tosh et al., 2010). Antibodies targeting the 
dominant surface protein, HA, tend to be directly neutralizing while those targeting NA have 
the potential to reduce viral replication efficiency by blocking NA sialidase activity and 
thereby impairing viral budding and spread (Eichelberger and Wan, 2015; Johansson et al., 
1989). Monoclonal antibodies (mAbs) are a rapidly advancing class of therapeutic proteins 
that possess wide clinical utility owing to their biocompatibility, high antigen specificity, and 
targeted immune stimulation dictated by the Fc subtype used. Here we describe a mAb that 
targets the NA of A(H7N9) and protects mice from lethal A(H7N9) challenge when 
administered in either a prophylactic or therapeutic setting.
2. Materials and methods
2.1. Animals, cells, viruses, and proteins
All research studies involving the use of animals were reviewed and approved by the 
Institutional Animal Care and Use Committee at the CDC in an Association for the 
Assessment and Accreditation of Laboratory Animal Care accredited facility. Six to eight 
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week old female BALB/c mice (The Jackson Laboratory) were used for all experiments. 
Mice were anesthetized by isoflurane inhalation for all intranasal (i.n.) instillations.
Immortalized B cells were maintained in IMDM supplemented with 10% ultra-low IgG FBS 
(HyClone). Influenza viruses were propagated in embryonated chicken eggs and titers were 
determined on MDCK cells by plaque assay. RG32a is a reverse-genetics reassortant virus 
containing the HA and NA from A/Shanghai/2/2013(H7N9) (“Sh/2”) with the 6 internal 
genes from A/Puerto Rico/8/1934(H1N1) (“PR8”). H6N9 is a reverse-genetics reassortant 
virus containing the HA from A/Turkey/CA/BENN/1973(H6N1), NA from Sh/2 (H7N9), 
and the remaining genes from PR8. The reverse-genetic reassortants were constructed by 
standard molecular biology techniques (Dong et al., 2009). A/Anhui/1/2013(H7N9) 
(“Anhui/1”), A/California/07/2009(H1N1pdm09) (“Ca/07”) and A/Perth/16/2009 (H3N2) 
(“Perth/16”) are wild-type viruses isolated from human infections. All work with RG32a 
was performed at Biosafety Level 2 enhanced containment, while Anhui/1 challenge studies 
were performed at Animal Biosafety Level 3-enhanced containment. The remaining viruses 
were handled under BSL2 containment.
The recombinant his-tagged NA (recNA) from Anhui/1, Ca/07, and Perth/16 were produced 
in a baculovirus expression system and purified as previously described (Wan et al., 2015; 
Yang et al., 2010). Monoclonal antibody to N3 NA of A/Canada/44/2004 (H7N3) (FR-969), 
N2 NA of A/Perth/16/2009 (H3N2) (FR-1155), and N1 NA of A/Brisbane/59/2007 (H1N1) 
(FR-933) were obtained from the Influenza Reagent Resource (IRR). mAb 0-1h6 to H7 HA 
of Sh/2 was produced by our laboratory using hybridoma technology (manuscript in 
preparation).
To generate a panel of recNA with a single mutation at solvent-exposed residues, a codon 
optimized cDNA encoding the ectodomain (residues 36-465) of the NA gene of Sh/2 was 
synthesized (GenScript USA Inc., NJ) and sub-cloned into pIEx-4 vector (EMD Millipore, 
MA) using the In-Fusion HD cloning system (Clontech, CA). All subsequent recNA mutants 
were generated from this wild type pIEx-4-NA clone using the QuickChange Lightning Site-
Directed Mutagenesis Kit (Stratagene, CA). Primer sequences used in mutagenesis PCR are 
available upon request. The resulting constructs were transiently transfected into sf9 cells 
(EMD Millipore, MA) using the Cellfectin II transfection reagent (Life Technologies, NY). 
All procedures were performed following protocols provided by manufacturers. The 
transfected cells were transferred into flasks and grown on a shaker at 27 °C for five days. 
All recNA proteins contained a His-Tag at the N-terminus followed by a tetramerization 
domain, from human vasodilator-stimulated phosphoprotein, and a thrombin cleavage site 
(Xu et al., 2008). The recNAs secreted in the culture supernatant were analyzed for their 
expression levels by western blot analysis. Supernatants were assessed using the MUNANA 
assay as described below to confirm correct conformation and functional activity of the 
mutated NA proteins (Yang et al., 2015). The recNA supernatants were used in biolayer 
interferometry assays without further purification.
2.2. Generation of mouse hybridoma secreting NA-specific mAb
Six to eight week old female BALB/c mice (The Jackson Laboratory) were immunized and 
boosted by intraperitoneal (ip) injection of 15 μg of a beta-propiolactone (BPL)-inactivated 
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and purified RG32a virus. Three days post-boost, splenocytes were fused with SP2/IL-6 
myeloma cells (American Type Culture Collection) using the ECM 2001 electrofusion 
apparatus (BTX Harvard Apparatus/Boston MA). After two brief washes with Cytofusion 
Medium C (BTX) the isolated lymphocytes were mixed with myeloma cells at a 1:1 ratio, 
resuspended at 10 × 106 cells/ml in Cytofusion Medium C and electrofusion was performed 
according to the manufacturer’s protocol. Fused cells were cultured in ClonaCell-HY 
Medium C (StemCell Technologies) for 48 h at 37 °C in a 5% CO2 incubator. Fused cells 
were centrifuged and re-suspended in 10 ml of ClonaCell-HY Medium C and then gently 
mixed with 90 ml of methylcellulose-based ClonaCell-HY Medium D (StemCell 
Technologies) containing HAT components, CloneDetect (Molecular Devices) and IL-6 
(Roche). The fused cells were plated into 100-mm petri dishes (BD Biosciences) and 
allowed to grow at 37 °C in a 5% CO2 incubator. After 10 days, single hybridoma clones 
were picked by ClonePix FL (Molecular Devices, Sunnyvale CA) based on anti-IgG FITC 
intensities from CloneDetect reagent and transferred to 96-well cell culture plates (BD 
Biosciences) with 200 μl/well IMDM and 20% serum. Hybridoma culture media was 
changed prior to ELISA screening. 3c10-3 was retrieved after 2 rounds of limiting dilution 
and clonality was confirmed by sequence analysis.
2.3. Production and purification of mAb
3c10-3 secreting hybridoma cells were expanded in CELLine™ Disposable Bioreactor 
(Corning) according to the manufacturers’ instructions. mAb 3c10-3 was subsequently 
purified from tissue culture supernatant using a protein G column (GE Healthcare).
2.4. Enzyme linked immunosorbent assay
For detection of NA reactivity, ELISA assays were performed as previously described 
(Wilson et al., 2014). Briefly, Costar Hi Bind plates (Corning Inc., Tewksbury, MA) were 
coated overnight with BPL-inactivated virus (25 HA units/well) or recNA (100 ng/well) at 
4 °C. Plates were blocked for 1 h with PBS/0.1% Tween-20 (PBST) containing 1.5% BSA 
(blocking buffer) at room temperature. All mAbs were serially titrated in blocking buffer and 
allowed to incubate with antigen-coated plates for 1 h at room temperature. After three 
PBST washes, wells were probed with goat anti-mouse (H&L)-HRP (Thermo Scientific) for 
1 h at room temperature. Plates were washed three times with PBST and signal was 
developed with 1 step™ Turbo TMB-ELISA reagent (Thermo Scientific). Reactions were 
stopped with 1 N sulfuric acid and absorbance was read at 450 nm.
2.5. Neuraminidase antibody inhibition assays
Antibodies with neuraminidase inhibition activity were detected using Enzyme-Linked 
Lectin assay (ELLA) as described previously (Couzens et al., 2014). Briefly, serial two-fold 
diluted mAb were incubated with an H6N9 reassortant virus, bearing the NA of Sh/2 but an 
unrelated HA, in 96 well plates coated with fetuin for 16–18 h. Following incubation, horse 
radish peroxidase-labeled peanut agglutinin (lectin) were added to the reaction and 
incubated for 2 h, followed by TMB substrate to reveal enzymatic cleavage of fetuin by viral 
NA. The percent inhibition of NA enzymatic activity at each serum dilution was calculated 
by comparison with values from virus control wells (virus but no serum). End-point NAI 
titers were calculated as the reciprocal of the highest dilution with at least 50% inhibition.
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For MUNANA-based neuraminidase inhibition assays, a series of 2-fold diluted purified 
recNA (Anhui/1) were mixed with 200 μM of MUNANA (Sigma-Aldrich) and a sigmoidal 
curve of NA generated. The recNA concentration (1.22 × 10−5 mg/ml) corresponding to the 
midpoint of the linear section of the curve was chosen for the inhibition assay. A series of 2-
fold diluted mAb were mixed with recNA at the fixed concentration of recNA and incubated 
at room temperature for 1 h, followed by standard procedures of MUNANA assay. The mAb 
IC50 was calculated by plotting the results on a semi-log graph in Excel.
2.6. Plaque reduction neutralization assay
For pre-infection treatment studies, 300–500 pfu of RG32a was incubated for 30 min with 
mAb at the indicated concentration followed by infection of a monolayer of Madin-Darby 
canine kidney (MDCK) cells in six-well plates. After 1 h incubation, cells were washed 4 
times with PBS and overlaid with agar supplemented with 1 μg/ml of trypsin without 
antibody. On day 3 post-infection, the agar overlay was removed, cells were fixed with 70% 
ethanol for 10 min, and plaques were visualized by staining with crystal violet. For post-
infection treatment studies, MDCK cells were first incubated with 300–500 pfu of RG32a in 
the absence of mAb for 1 h and washed accordingly. The cells were then overlaid with agar 
supplemented with 1 μg/ml trypsin and the indicated concentration of mAb. Plaques were 
visualized as indicated above on day 3 post-infection. mAb 0–1h6, targeting the HA of Sh/2, 
was generated by our laboratory (manuscript in preparation) and served as positive control 
while mouse-IgG1, a kappa isotype-matched mAb (Crown Bioscience Inc.), served as 
negative control. To determine plaque size, images were imported into ImageJ2 and 10 
random plaques were measured for each condition using the drawing tool, converted to 
millimeters2, and compared to the control plaques, respectively.
2.7. Prophylactic and therapeutic efficacy studies
To examine the prophylactic efficacy of 3c10-3, 6–8 week old female BALB/c mice (The 
Jackson Laboratory) (N = 5 per group) were passively immunized by intraperitoneal (i.p.) 
injection with the indicated dose of mAb in a final volume of 200 μl. Control mice received 
mouse IgG1, kappa isotype-matched mAb (Crown Bioscience Inc.) or saline. 24 h post 
transfer, mice were challenged with 5 MLD50 of Anhui/1 H7N9 by intranasal instillation. 
Mice were anesthetized by isoflurane inhalation for all intranasal (i.n.) instillations and the 
total volume did not exceed 50 μl.
To examine the therapeutic efficacy of 3c10-3, 6–8 week old female BALB/c mice (N = 5 
per group) were challenged with 5 MLD50 of Anhui/1 and treated 1, 2 or 3 days later with a 
single instillation of mAb (i.p.) at the indicated dose. Control mice received a single 
instillation of 2 mg/kg mouse-IgG1, kappa isotype-matched mAb (Crown Bioscience Inc.) 1 
day post infection. Mice were monitored daily for body weight and mortality for 14 days 
post-challenge. Mice reaching ≥25% weight loss were euthanized.
2.8. Binding kinetics and epitope mapping
Using biolayer interferometry (BLI) on the Octet Red96 System (ForteBio, Inc., Menlo 
Park, CA) the binding kinetics for mAb 3c10-3 binding to Anhui/1 recNA containing either 
R289 (wild type) or K289 was assessed, as previously described (Sleeman et al., 2013; 
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Wilson et al., 2014). For epitope mapping BLI was used to determine 3c10-3 binding to a 
panel of recNAs with single surface exposed point mutations (Fig. 2a), as compared to wild-
type Anhui/1 as previously described (Sleeman et al., 2013; Wilson et al., 2015). Briefly, 
expression levels of each mutated recNA were determined by western blot and the amount of 
recNA used in biosensor loading was normalized for equal loading. Anti-HIS biosensors 
(ForteBio, Inc.) were loaded with a constant amount of each recNA, followed by analysis of 
antigen-antibody interaction using protocols provided by the manufacturer. Unless otherwise 
specified, all amino acid residue numbers are in N9 numbering. Data are presented as 
percentage of antibody binding to mutant recNA compared to WT recNA (100%). A 
reduction of ≥50% in binding response for each mutant compared to the WT recNA was 
considered significant (Throsby et al., 2008).
3. Results
3.1. 3c10-3 inhibits A/H7N9 virus NA activity
Splenocytes from a mouse immunized with BPL-inactivated A(H7N9) (RG32a) were fused 
with Sp2/IL6 myeloma cells. A hybridoma secreting mAb 3c10-3 was identified by 
screening for recN9 reactivity by ELISA. IgH and IgL sequence analysis confirmed that the 
hybridoma secreting 3c10-3 is clonal and of the isotype IgG1/Kappa (data not shown). 
3c10-3 binds the recNA of Anhui/1 detectably at very low concentration (<5 ng/ml) and did 
not detectably bind the recNA of Ca/07 (N1) or Perth/16 (N2) (Table 1).
To determine if 3c10-3 is capable of inhibiting the enzymatic activity of N9 in vitro, an 
enzyme-linked lectin assay (ELLA) and MUNANA assay was employed. 3c10-3 decreased 
the cleavage of the large substrate fetuin by Sh/2 N9 by 50% at a very low concentration (<4 
ng/ml) and also demonstrated the ability to decrease Anhui/1 recN9 cleavage of the small 
substrate MUNANA at 6051 ng/ml (Table 1).
To further characterize 3c10-3 inhibition of NA enzymatic activity on the virus life cycle, 
plaque reduction assays were performed. The presence of 3c10-3 was shown to reduce 
A(H7N9) (RG32a) plaque size when supplemented into the agar overlay (Fig. 1b and Fig. 
1c, right panel) while having minimal effect on plaque size when virus was only treated with 
3c10-3 prior to infection (Fig. 1a and c, left panel) indicating that 3c10-3 inhibits cell-to-cell 
virus spread. As a control, anti-H7 mAb 0–1h6, which targets the HA1 domain of A(H7N9) 
(manuscript in preparation), directly neutralized virus infection and inhibited virus spread 
under the respective conditions.
3.2. 3c10-3 binds near the enzyme active site of NA
To determine critical residues involved in the binding footprint of the NA/3c10-3 complex, 
we developed a panel of 22 recNA, each containing a single point mutation of a surface 
exposed residue relative to that of the NA of Sh/2 (Fig. 2a), and tested their binding affinity 
as determined by BLI. A decrease of ≥50% binding activity was our cutoff for significance. 
Compared to wild type NA, a significant reduction in binding affinity was noted with NA 
encoding a change at residues T244, P338, N340, N342, K429 and D431 (Fig. 2b). A 
significant increase in off rate was also observed with changes at N341 and A365, a strong 
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indication that these residues also contribute to the binding activity of 3c10-3 to NA. These 
mutated NAs with altered binding patterns to 3c10-3 were confirmed to have correct 
conformations as they were found to maintain similar neuraminidase activities in MUNANA 
assays and could be recognized by other N9 monoclonal antibodies (data not shown). These 
data imply that 3c10-3 directly inhibits the enzymatic activity of N9 NA by binding across 
the enzymatic active site (Fig. 2c).
3.3. 3c10-3 binds neuraminidase inhibitor resistant NA
The NA of A/Shanghai/1/2013(H7N9) has been shown to be resistant to the NA inhibitor, 
oseltamivir, due to a R289K substitution in the enzyme active site (Wu et al., 2013).
To determine if 3c10-3 maintains the ability to bind NA carrying the R289K substitution, 
recNA encoding this mutation was constructed and binding kinetics were determined using 
BLI. 3c10-3 bound both R289 and K289-containing NA with similar affinity, suggesting that 
3c10-3 may be an alternative treatment option for NAI resistant viruses (Table 2).
3.4. Prophylactic administration of 3c10-3 protects mice against lethal challenge infection
Prophylactic administration of anti-influenza mAb to individuals that are in close contact 
with an A(H7N9) infected human or poultry could be of great value. To evaluate the 
protective efficacy of 3c10-3 in vivo, mice were administered 10, 2 or 0.4 mg/kg of 3c10-3 
i.p. 24 h prior to an i.n. challenge with 5 times the 50% mouse lethal dose (5MLD50) of 
Anhui/1 virus. Control mice received 10 mg/kg of isotype-matched mAb or saline, as 
indicated. Systemic administration of a single dose of 3c10-3 protected all mice from death 
for each experimental dose (Fig. 3) and resulted in ≤10% weight loss for the lowest dose 
tested (0.4 mg/kg) (Fig. 3). In contrast, day 8 post challenge, 60% of the isotype control and 
80% of the saline control mice were sacrificed due to a >25% loss of weight (Fig. 3). 
Overall, these results indicate that 3c10-3 protects mice from A(H7N9) lethality and weight 
loss in a dose-dependent manner when administered prophylactically.
3.5. Therapeutic administration of 3c10-3 up to 72 h post lethal challenge protects mice 
from mortality
The ability of 3c10-3 to protect mice from a lethal A(H7N9) virus challenge when 
administered in the period after infection was tested to simulate a clinical situation. Mice 
were challenged with 5 MLD50 Anhui/1 and subsequently treated with a single dose of 
either 2 mg/kg or 0.4 mg/kg of 3c10-3 (i.p.) on day 1, 2 or 3 post-infection. Mice that 
received 2 mg/kg of isotype-matched mAb on day 1 post-infection served as control for all 
groups. Systemic administration of a single dose of 2 mg/kg on day 1 post-challenge 
protected all mice against death, while 80% were protected when the same dose was given 
on day 2 or 3 post-challenge. A single dose of 0.4 mg/kg conferred 20 and 60% protection 
against death when administered day 1 or 2 post-challenge respectively. None of the mice 
survived after receiving isotype matched mAb, or when 0.4 mg/kg of 3c10-3 was 
administered on day 3 post-challenge (Fig. 4).
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4. Discussion
Avian A(H7N9) viruses continue to infect humans, especially in Asia, and pose a pandemic 
threat. NAI’s are currently the only clinically available class of antiviral drugs for treatment 
of A(H7N9) infections. However, the emergence of A(H7N9) viruses with resistance to 
NAI’s remains a concern. Here we show that the anti-NA mAb 3c10-3 protects mice from 
lethal challenge with A(H7N9) virus, and reduces morbidity and mortality when used 
therapeutically in already-infected mice. Although a number of anti-NA mAbs with 
protective efficacy in vivo have been described recently (Doyle et al., 2013; Jiang et al., 
2013; Shoji et al., 2011; Wan et al., 2013; Wohlbold et al., 2016), this is the first report of an 
anti-N9 mAb that has therapeutic activity.
We performed antigenic mapping of 3c10-3 to identify the region of NA with which it 
interacts. In comparison to influenza hemagglutinin, antigenic sites on NA are poorly 
understood. Epitope mapping of the N1, N2, N8 and N9 subtypes, using mAb to select 
escape mutants, has revealed roughly 30 amino acids critical for antibody-NA binding 
(reviewed; (Air, 2012; Eichelberger and Wan, 2015)). The most thoroughly studied anti-N9 
mAb include NC10 and NC41 that were raised against A/tern/Australia/G70C/1975 (H11/
N9). The three-dimensional structure of these mAb in association with their substrate, 
revealing their binding footprint, has been determined (Air et al., 1990; Malby et al., 1994; 
Tulip et al., 1992a; Webster et al., 1987). Of the eight amino acids identified as essential for 
their binding to N9 (Air et al., 1990; Tulip et al., 1992b), one (365) was also identified in our 
epitope mapping, indicating that 3c10-3 has an overlapping footprint with these two N9-
specific mAb and suggesting that this may be an immunodominant region. Crystallography 
study on the 3c10-3 and N9 complex are currently under way and will provide further 
information on how this mAb binds to its target.
The finding that 3c10-3 spans the enzyme active site of N9 is consistent with the profound 
functional inhibition of NA activity, including the cleavage of both small and large substrate, 
this antibody causes. The N9 amino acids identified in the binding of 3c10-3 to the NA of A/
H7N9 are highly conserved amongst all known N9 isolates, ranging from 97.4% to 99.7% 
identity, based on sequence analysis of 649 unique N9 sequences deposited in GISAID (as 
of 9-16-2016; Data not shown). Variation in these residues may be of particular importance 
for antigenic drift of A(H7N9) viruses, and should be monitored as part of the ongoing 
surveillance of A(H7N9) viruses in human and animal reservoirs. More importantly, epi-
topes of 3c10-3 are not overlapping R289, a residue known to confer NAI resistance in 
Group 2 NA when mutated (R292 in N2 numbering (Sleeman et al., 2013)), making it a 
better option for control of A(H7N9) NAI-resistant viruses.
Apart from the NA active site, a second receptor binding site with hemagglutinating activity 
has been reported for the N9 subtype of NA (Laver et al., 1984). The residues that reacted 
with sialic acid (Varghese et al., 1997) are highly conserved within currently circulating 
H7N9 isolates, indicating these recent isolates may also have this ability. Interestingly, two 
(A365 and K429) of the N9 amino acids we identified as part of the 3c10-3 footprint are also 
part of this sialic acid binding site. This suggests that, if the hemadsorbing activity of N9 is 
maintained in contemporary A/H7N9 viruses, 3c10-3 would also inhibit this activity.
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Influenza vaccines are standardized by the amount of HA contained in each dose and 
traditionally, influenza vaccine studies have focused on measurement of anti-HA antibody 
responses as correlates of protection. However, it is well known that anti-NA antibodies also 
can confer some protection (Monto and Kendal, 1973; Murphy et al., 1972; Schild, 1969), 
although the level of NA in split vaccines vary and currently are not standardized. The 
growing number of reports detailing the protective efficacy of anti-NA mAb in vivo (Doyle 
et al., 2013; Jiang et al., 2013; Shoji et al., 2011; Wan et al., 2013; Wohlbold et al., 2016), 
further support a re-emphasis on including anti-NA antibody responses in the analysis of 
protection against influenza infection and provides additional support for standardizing the 
amount of NA contained in each vaccine dose.
Our findings demonstrate that 3c10-3 can effectively prevent A(H7N9) lethality on its own. 
There have also been reports on the efficacy of mAb(s) against the HA of A(H7N9) virus 
infections in the mouse model (Chen et al., 2015; Dunand et al., 2015; Tan et al., 2016; 
Tharakaraman et al., 2015). Since treatment with 3c10-3, or the above mentioned HA-
targeting mAb, alone both prevents and treats influenza virus infection, it seems plausible 
that an antibody cocktail targeting both influenza HA and NA may be a viable therapeutic 
approach, or could be administered to at-risk individuals (e.g. those in close contact with 
infected humans or poultry) as a prophylactic measure. Such a combination therapy 
approach may reduce the potential risk of the development of A(H7N9) escape mutants 
induced by monotherapy. Since 3c10-3 is of murine origin, humanization of this mAb could 
potentially increase its therapeutic value in humans by avoiding a human anti-mouse 
antibody response; this work is currently in progress.
Although we demonstrate that 3c10-3 is capable of direct inhibition of NA enzymatic 
activity and of virus spread in vitro, the mechanism of action affording protection in vivo is 
likely to be a combination of inhibition of NA enzyme activity coupled with Fc receptor-
guided effector functions such as complement-mediated and/or antibody-dependent cell-
mediated cytotoxicity (ADCC). Studies are currently under way to better understand the 
mechanisms of 3c10-3 protective efficacy in vivo.
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Fig. 1. 3c10-3 reduces A(H7N9) plaque size when supplemented in media post-infection but does 
not prevent infection
(A) Virus was incubated with the indicated concentration of mAb prior to infection of the 
MDCK monolayer. The infection overlay did not contain any mAb. (B) The MDCK 
monolayer was infected with virus and the indicated concentration of mAb was incorporated 
into the infection overlay. Cells were infected for 72 h prior to visualization. mAb 0–1h6 
binds the HA1 domain of H7 HA and served as a positive control. (C) Diameters of RG32a 
plaque size were determined for both panel A (left) and B (right) by randomly selecting and 
measuring 10 plaques in ImageJ2. Diameters significantly different compared to those of the 
isotype control mAb (P < 0.05) are indicated by lines and asterisks, respectively.
Wilson et al. Page 13
Antiviral Res. Author manuscript; available in PMC 2017 December 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 2. Epitope map of 3c10-3 as determined by Biolayer Interferometry (BLI)
(A) Location of the amino acid position of 22 individual mutant recNA developed on a NA 
monomer of the 3-dimensional structure of a N9 tetramer (PDB accession code 4MWJ). The 
mutant panel is primarily based on previously identified essential amino acids of mAb 
binding to NA. Red; N1 (Wan et al., 2013), blue; N2 (Gulati et al., 2002; Lentz et al., 1984; 
Webster et al., 1984), cyan; N9 (Air et al., 1990; Tulip et al., 1992a; Tulip et al., 1992b), 
yellow; N8 (Saito et al.,1994) and orange; unique selected by us. (B) 3c10-3 binding affinity 
to each mutant recNA and the percent response compared to wild-type Sh/2 recNA was 
determined. A greater than 50% reduction in binding activity was the cutoff for significance. 
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“ ” signifies a mutation that resulted in an increased off rate. (C) The location of residues 
changes that reduce binding affinity, as identified by BLI, on the 3-dimensional structure of 
a NA monomer (PDB accession code 4MWJ). Gray; 3c10-3 epitope, green; enzyme active 
site (Air, 2012) and magenta; NAI resistance mutation (Sleeman et al., 2013). Red text 
indicates residue changes that significantly increased the 3c10-3 off rate. The structural 
figures were generated with PyMol software (Schrodinger).
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Fig. 3. Intraperitoneal delivery of mAb 3c10-3 affords prophylactic protection against A(H7N9) 
lethal challenge
Six to eight week-old female BALB/c mice (n = 5 per group) were injected i.p. with 0.4, 2, 
or 10 mg/kg of mAb 3c10-3 and 24 h later infected with 5MLD50 of Anhui/1 virus. The 
percentage of initial body weight (mean ± std) and survival are shown. Control groups 
received 10 mg/kg of isotype-matched control antibody (IGg1/Kappa) or saline.
Wilson et al. Page 16
Antiviral Res. Author manuscript; available in PMC 2017 December 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 4. Intraperitoneal delivery of 3c10-3 affords therapeutic protection following A(H7N9) lethal 
challenge
Six to eight week-old female BALB/c mice (n = 5 per group) were infected with 5MLD50 of 
Anhui/1 and later injected i.p. with 2 or 0.4 mg/kg of mAb 3c10-3 on d 1, 2 or 3 post-
challenge. The percentage of initial body weight (mean ± std) and survival are shown. 
Control mice received 2 mg/kg of isotype-matched antibody (IGg1/Kappa) on d 1 post-
challenge served as control.
Wilson et al. Page 17
Antiviral Res. Author manuscript; available in PMC 2017 December 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Wilson et al. Page 18
Ta
bl
e 
1
In
 v
itr
o 
ac
tiv
ity
 o
f 3
c1
0-
3.
 m
A
b 
w
er
e 
sc
re
en
ed
 b
y 
EL
IS
A
 fo
r r
ea
ct
iv
ity
 to
 th
e 
in
di
ca
te
d 
re
cN
A
 a
nd
 fu
rth
er
 sc
re
en
ed
 fo
r N
A
 e
nz
ym
e 
in
hi
bi
tio
n 
by
 E
LL
A
 
an
d 
M
U
NA
N
A
.
EL
IS
A
 (n
g/m
l)a
EL
LA
 (n
g/m
l)b
M
U
N
A
N
A
 (n
g/m
l)b
A
nh
ui
/1
 re
cN
9
C
A
/0
7 
re
cN
1
Pe
rt
h/
16
 re
cN
2
Sh
/2
 H
6N
9
A
nh
ui
/1
 re
cN
9
3c
10
-3
4.
88
>
50
00
>
50
00
3.
12
5
60
51
FR
-9
69
 (A
nti
-N
3)
>
50
00
>
50
00
>
50
00
>
25
00
>
50
,0
00
FR
-1
15
5 
(A
nti
-N
2)
>
50
00
>
50
00
19
.5
3
>
25
00
>
50
,0
00
FR
-9
33
 (A
nti
-N
1)
>
50
00
12
50
>
50
00
>
25
00
>
50
,0
00
a D
at
a 
ar
e 
sh
ow
n
 a
s 
th
e 
m
in
im
um
 m
A
b 
co
nc
en
tra
tio
n 
re
qu
ire
d 
to
 p
ro
du
ce
 a
 2
-fo
ld
 si
gn
al
 a
bo
v
e 
n
eg
at
iv
e 
co
n
tr
ol
..
b D
at
a 
ar
e 
sh
ow
n
 a
s 
th
e 
m
in
im
um
 c
on
ce
nt
ra
tio
n 
of
 a
nt
ib
od
y 
re
qu
ire
d 
to
 in
hi
bi
t 5
0%
 o
f e
nz
ym
e a
ct
iv
ity
.
Antiviral Res. Author manuscript; available in PMC 2017 December 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Wilson et al. Page 19
Ta
bl
e 
2
3c
10
-3
 b
in
di
ng
 k
in
et
ic
s t
ow
ar
d 
w
ild
 ty
pe
 a
nd
 re
cN
9 
w
ith
 N
A
I r
es
ist
an
ce
.
K
D
 
(M
)
K
D
 
er
ro
r
k o
n
(m
s−1
)
k o
n
 
er
ro
r
k d
is(s
−
1 )
k d
is 
er
ro
r
A
/A
nh
ui
/1
 re
cN
9
2.
34
 ×
 1
0−
09
7.
06
 ×
 1
0−
11
1.
72
 ×
 1
00
5
1.
05
 ×
 1
00
3
4.
01
 ×
 1
0−
04
1.
19
 ×
 1
0−
05
A
/A
nh
ui
/1
 re
cN
9 
(R
28
9K
)
3.
11
 ×
 1
0−
09
7.
42
 ×
 1
0−
11
1.
65
 ×
 1
00
5
1.
00
 ×
 1
00
3
5.
14
 ×
 1
0−
04
1.
19
 ×
 1
0−
05
Antiviral Res. Author manuscript; available in PMC 2017 December 14.
